Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 12, Issue 9, Pages 1486-1492Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.1c00349
Keywords
Designer aminoglycosides; nonsense mutations; genetic diseases; premature termination codon readthrough
Categories
Funding
- Versant Ventures
Ask authors/readers for more resources
Aminoglycosides have the potential to induce readthrough of premature termination codons, which could be valuable in treating genetic diseases. Modification of aminoglycoside compounds to reduce cellular toxicity while maintaining readthrough activity is a strategy documented in this study.
A significant proportion of genetic disease cases arise from truncation of proteins caused by premature termination codons. In eukaryotic cells some aminoglycosides cause readthrough of premature termination codons during protein translation. Inducing readthrough of these codons can potentially be of therapeutic value in the treatment of numerous genetic diseases. A significant drawback to the repeated use of aminoglycosides as treatments is the lack of balance between their readthrough efficacy and toxicity. The synthesis and biological testing of designer aminoglycoside compounds is documented herein. We disclose the implementation of a strategy to reduce cellular toxicity and maintain readthrough activity of a library of compounds by modification of the overall cationic charge of the aminoglycoside scaffold through ring I modifications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available